Following his recent publication in the Lancet Respiratory Medicine, and presentation at the ERS Congress, we spoke with Prof. Liam Heaney (Queen’s University, Belfast, Northern Ireland, UK) about the composite biomarker approach to optimising steroid dosage in patients with severe asthma.
- Why is there a need for new approaches to optimising steroid dosage in people with severe asthma? (0:11)
- Could you give us a brief overview of the composite biomarker approach to optimising steroid dosage? (1:06)
- Could you tell us a little about your recent study comparing this approach with a symptomatic/risk/based algorithm? (2:23)
- What were the major findings of this study in terms of clinical and patient-reported outcomes? (4:19)
- What will be the impact of these findings on clinical practice and what future studies are planned? (6:10)
Speaker disclosure: Liam Heaney has received grant funding and taken part in advisory boards and given lectures at meetings supported by Hoffmann-La Roche–Genentech and Aerocrine. He has also taken part in asthma clinical trials sponsored by Hoffmann-La Roche–Genentech, and is an Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma, which involves industrial partnerships with a number of pharmaceutical companies, including Hoffman-La Roche and Aerocrine.
Support: Interview and filming supported by Touch Medical Media. Niche Science and Technology were given the opportunity to review the video. No changes to the video were made as a result.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In Asthma
Antonio Spanevello: Research Highlights from 2021
We were delighted to talk with our Editorial Board member Professor Antonio Spanevello (University of Insubria, Varese, Italy) around his research highlights from 2021 in the field of airway inflammation and asthma. Question Is the evaluation of airway inflammation important in detecting the different phenotypes of bronchial asthma? (0:26) Disclosures: Antonio Spanevello has nothing to […]
Njira Lugogo, CHEST 2021: Tezepelumab for the Treatment of Severe, Uncontrolled Asthma
It was a pleasure to meet with Professor Njira Lugogo (University of Michigan, Ann Arbor, MI, USA) to discuss the findings from the NAVIGATOR study, investigating tezepelumab in adults and adolescents with severe, uncontrolled asthma (NCT03347279). The abstract ‘TEZEPELUMAB PRODUCES CLINICALLY MEANINGFUL RESPONSES ON PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA: RESULTS FROM […]
Njira Lugogo, CHEST 2021: Updates in Asthma Treatment
We were delighted to catch up with Professor Njira Lugogo (University of Michigan, Ann Arbor, MI, USA) around her presentation ‘Asthma Management: New Insights’, which was presented at CHEST 2021, 17-20 October 2021. Questions What has recent research taught us about the heterogeneity of asthma? (0:12) What are the most promising potential future biomarkers for […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!